<DOC>
	<DOCNO>NCT02780622</DOCNO>
	<brief_summary>This open-label , randomize , 2-period crossover study , evaluate pharmacokinetics , pharmacodynamics , safety tolerability warfarin combination Tamiflu ( oseltamivir ) participant stabilize warfarin . Participants randomize receive either warfarin follow oseltamivir warfarin , oseltamivir warfarin follow warfarin . The treatment period separate washout period least 4 day . Participants continue receive warfarin daily prescribe usual dose throughout study .</brief_summary>
	<brief_title>A Pharmacokinetics , Pharmacodynamics Safety Study Warfarin Combination With Tamiflu ( Oseltamivir )</brief_title>
	<detailed_description />
	<mesh_term>Oseltamivir</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Participants must receive warfarin daily least 4 week prior Screening Participants must regular International Normalized ratio ( INR ) monitoring warfarin therapy prior study entry , willing train use CoaguCheck device INR must fall within target range 2.03.5 Body mass index ( BMI ) 1832 kg/m^2 inclusive An INR value screen Day 1 low 2.0 great 3.5 A change prescribe daily warfarin dose Screening Day 1 History coagulopathy Consumption health product supplement contain vitamin K Pregnant lactate woman Confirmed positive urine and/or blood test drug abuse Screening Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>